Worst pipeline in the industry -- dead in the water until 2008. Jury will be out on relatively new director of research and whether he can reconstruct without acquisition, but the rest of management is bottom quarter in the industry. You could put a blindfold on a monkey and throw darts at a list of old-line pharma and wind up with a better choice.